Can two drugs together tackle tough lung cancer?
NCT ID NCT04797702
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial is testing whether combining two drugs—glumetinib and toripalimab—can help people with advanced non-small cell lung cancer that has not responded to or is no longer controlled by standard treatments. The study is enrolling adults whose cancer has a specific marker (PD-L1 expression of 1% or higher) and who do not have certain genetic mutations. The goal is to see if the combination is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a combination of two drugs: glumetinib (a MET inhibitor) and toripalimab (an immunotherapy)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced non-small cell lung cancer who have run out of standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits and risks are not yet clear. The combination may cause significant side effects, and it is unknown if it will work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
6 people
The number who actually took part.
- Started
-
Apr 2021
- Finished
-
Nov 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: 1. Subsubjects with histologically or cytologically confirmed NSCLC, clinically diagnosed as locally advanced (stage IIIB or IIIC) and stage IV NSCLC (according to AJCC 8th edition staging), EGFR wild-type, negative for ALK and ROS1 rearrangement, and no Met exon14 skipping mutation; genetic testing is not mandatory for subjects with squamous cell cancer; 2. PD - L1 expression of 1% or higher. 3. Non-small cell lung cancer patients following failure of or were intolerance to previous standard treatment (chemotherapy and immunotherapy alone or in combination) and received no more than third-line treatment; 4. At least 1 measurable tumor lesion according to RECIST1.1 criteria. 5. Subjects must provide valid and qualified tissue samples (fresh biopsy or preserved tumor tissue samples are acceptable, but fresh biopsy samples are preferred). 6. ECOG score ≤1 point; 7. Sufficient function of bone marrow, liver and kidney organs. Exclusion criteria: 1. Pathological diagnosis confirmed the presence of small cell lung cancer; 2. The patient was currently participating in and receiving other studies or had previously received another c-Met inhibitor; 3. There are mutations/rearrangements of EGFR, ALK, ROS1, Met14 exon skipping;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Relapsed or metastatic non-small cell lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510180, China